FindTrial
Sign In

Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Mayo Clinic

Conditions

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Human Papillomavirus-Related CarcinomaLocally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise SpecifiedLocally Advanced Oropharyngeal CarcinomaStage IB3 Cervical Cancer FIGO 2018Stage II Cervical Cancer FIGO 2018Stage IIA Cervical Cancer FIGO 2018Stage IIA1 Cervical Cancer FIGO 2018

Phase 1

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
CompletedNCT05232851
Mayo ClinicClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma +2
Start: 2022-06-16End: 2025-04-09Updated: 2026-02-10

Phase 2

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
Active, not recruitingNCT04580771
M.D. Anderson Cancer CenterLocally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018 +11
Start: 2020-10-14End: 2027-03-08Updated: 2025-10-10

Related Papers

Initial results of MC200710 investigating therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma, a phase 2 window of opportunity trial.
Journal of Clinical Oncology2025-05-282 citations
674 IMMUNOCERV, an ongoing phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers
Regular and Young Investigator Award Abstracts2022-11-014 citations